Armata Pharmaceuticals, Inc. (FRA:TG1N)
Germany · Delayed Price · Currency is EUR | Market Cap | 177.15M +114.0% |
| Revenue (ttm) | 4.85M -19.3% |
| Net Income | -168.21M |
| EPS | -4.61 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 4.720 |
| Previous Close | 4.380 |
| Day's Range | 4.720 - 4.720 |
| 52-Week Range | 1.970 - 12.700 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 12, 2026 |
About Armata Pharmaceuticals
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company’s product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA03 for Pseudomonas aeruginosa . The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc. [Read more]
Financial Performance
In 2025, Armata Pharmaceuticals's revenue was $4.90 million, a decrease of -5.22% compared to the previous year's $5.17 million. Losses were -$173.80 million, 818.8% more than in 2024.
Financial numbers in USD Financial StatementsNews
Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update
LOS ANGELES, Aug. 12, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of hig...
Armata Pharmaceuticals Earnings release: Q2 2026
Armata Pharmaceuticals released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Armata Pharmaceuticals Quarterly report: Q2 2026
Armata Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 12, 2026.
Armata Pharmaceuticals Slides: Corporate presentation
Armata Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on July 30, 2026.
Armata provides update on AP-SA02 studies
Armata Pharmaceuticals (ARMP) announced significant clinical, regulatory, manufacturing and operational progress supporting advancement of AP-SA02, the Company’s intravenously administered Staphylococ...
Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02
FDA submissions address all feedback on clinical, CMC, and regulatory topics from the End-of-Phase 2 meeting Four AP-SA02 engineering runs completed; clinical trial material production is the next pla...
Armata Pharmaceuticals reaches agreement with FDA on iPSP for AP-SA02
Armata Pharmaceuticals (ARMP) announced that it has received agreement from the U.S. FDA on an Agreed Initial Pediatric Study Plan, which establishes the agreed regulatory framework for the future eva...
Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia
Fulfills important regulatory milestone for AP-SA02 on the path toward a future BLA and supports expansion into pediatric patients LOS ANGELES, July 13, 2026 /PRNewswire/ -- Armata Pharmaceuticals, In...
Armata Pharmaceuticals granted $2.5M additional non-dilutive award funding
Armata Pharmaceuticals (ARMP) has received an additional $2.5M of non-dilutive funding pursuant to a previously announced Department of Defense award, received through the Medical Technology Enterpris...
Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02
Supports Phase 3 readiness of AP-SA02 Non-dilutive DoD funding totals $28.7M to date LOS ANGELES, June 23, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Com...
Armata Pharmaceuticals Slides: Corporate presentation
Armata Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on June 11, 2026.
Armata Pharmaceuticals reports Q1 EPS ($3.16) vs. (20c) last year
Reports Q1 revenue $0.8M vs. $0.5M last year. “Our top priority in 2026 is advancing Armata’s lead Staphylococcus aureus therapeutic phage candidate, AP-SA02, into a Phase 3 superiority study in…
Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update
Entered into secured credit agreement with Innoviva for $25 million maturing in 2029 LOS ANGELES, May 13, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Comp...
Armata Pharmaceuticals Quarterly report: Q1 2026
Armata Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 13, 2026.
Armata Pharmaceuticals Earnings release: Q1 2026
Armata Pharmaceuticals released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Armata Pharmaceuticals secures FDA Fast Track Designation for AP-SA02
Armata Pharmaceuticals (ARMP) announced that the U.S. FDA has granted Fast Track Designation to AP-SA02, the company’s intravenously administered Staphylococcus aureus multi-phage product candidate, f...
Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02
Enables more frequent FDA engagement, rolling Biologic License Application review, and the potential for Accelerated Approval and Priority Review upon successful clinical development Advances AP-SA02 ...
Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"
Describes structure of phage P7-1, included in Armata's Pseudomonas aeruginosa phage cocktail, AP-PA02 LOS ANGELES, May 4, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Arm...
Armata Pharmaceuticals Proxy statement: Proxy filing
Armata Pharmaceuticals filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D.
LOS ANGELES, April 27, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of hi...
Armata Pharmaceuticals price target raised to $20 from $15 at JonesResearch
JonesResearch analyst Debanjana Chatterjee raised the firm’s price target on Armata Pharmaceuticals (ARMP) to $20 from $15 and keeps a Buy rating on the shares. After speaking with key opinion…
Armata Pharmaceuticals reports Q4 EPS ($3.42) vs. (23c) last year
The company recognized grant revenue of $1.1M for the three months ended December 31, 2025 as compared to $1.2M in the comparable period in 2024, which represents MTEC’s share of…
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results
LOS ANGELES, March 25, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of hi...
Armata Pharmaceuticals Annual report: Q4 2025
Armata Pharmaceuticals has published its Q4 2025 annual report on March 25, 2026.
Armata Pharmaceuticals Earnings release: Q4 2025
Armata Pharmaceuticals released its Q4 2025 earnings on March 25, 2026, summarizing the period's financial results.